Navigation Links
Week in Review in the Health Outcomes and Pharma Pricing Field from HealthEconomics.Com
Date:2/15/2013

Ponte Vedra Beach, Florida (PRWEB) February 15, 2013

The top news story available on HealthEconomics.Com explored results of a study by the European Consortium in Healthcare Outcomes (ECHOUTCOME) claiming that the QALY (quality-adjusted life years) has failed as a common metric for assessing cost-benefit of drug therapies. The findings have set off a controversial debate on the continued use of the QALY as a measure for deciding whether or not a drug will be reimbursed by payers or health systems. The QALY is used by NICE (the National Institute for Health and Clinical Excellence) for coverage decisions by the National Health Service in the United Kingdom, as well as by Canada and Australia. Generally if a treatment costs more than £20,000-30,000 per QALY, it would not be recommended as cost-effective by NICE.

The study findings caused a backlash of protests by UK-based experts, defending the current system and NICE called the study "limited". More details on the QALY debate can be found on HealthEconomics.Com News.

Another popular news story related to the Pharmacy Benefit Management (PBM) sector. Costco, the largest warehouse club chain in the United States, has entered into the PBM marketplace with the intent to offer services to small and medium-sized companies located near their warehouse stores. Currently, Express Scripts Holding and CVS Caremark dominate the PBM business. PBMs play a significant role in drug coverage decisions and can dramatically impact the success or failure of a pharmaceutical drug product’s success in the marketplace. For more on the impact of Costco on the PBM marketplace, visit the

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Up to the Challenge: Careers in Science in the Midst of Drastic Change, According to Wysebridge Patent Bar Review
2. Sigma-Aldrich Corporation Will Hold Its Annual Business Review March 21, 2013
3. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
4. Wysebridge Patent Bar Review Discusses Major Changes To The Patent Bar Exam
5. New EMR Comparison Website Launches Crowdsourcing Electronic Medical Record Software Reviews and Comparisons
6. Independent Marketing Automation Software Expert gives Positive review on MindMatrix's platform, AMP
7. Global Metabolomics Market Reviewed & Forecast in New In-Demand Report Available at MarketPublishers.com
8. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
9. Wysebridge Patent Bar Review Announces the Launch of News Blog
10. Review Module Headlines BSI 8.6 Release for Enterprise Biobank Software
11. The 2013 CES: Patents, Legislation Reform, and the Growing Market for Patent Attorneys and Agents Reviewed by Wysebridge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  Prima Biomed Ltd. (NASDAQ: PBMD ) a ... a leader in the development of immunotherapeutic products for ... CVac data from the Phase II CAN-003 ovarian cancer ... clinically meaningful improvement in Overall Survival ("OS") over standard ... In the group of second remission patients (n=20), the ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... , May 20, 2015 Research and ... the addition of the "2015 Global Survey ... their offering. The primary goal of ... flow cytometry instruments and reagents. Key information the ... the selection of flow cytometers, predominantly used applications ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
... Sept. 10 Signalife, Inc. (Amex:,SGN) announced that the company,s ... stock to be effected in the form of a,reverse stock ... on September,19, 2008, which will be the record date and ... time of such reverse stock split, all,outstanding shares of Signalife ...
... 10 , - Abstracts 185 and 1112, ... announced results from,two randomized clinical studies presented at ... 44th Annual Meeting demonstrating that the,"basal plus" insulin ... daily (basal insulin) and APIDRA(R) once daily,(prandial insulin) ...
... Sept. 10 Abeome Corporation, a,Georgia-based biotech company, ... (SAB) to collaborate on the development of,Abeome,s ovarian ... therapeutic,and diagnostic projects for the company., The ... Meagher, PhD, Chief,Scientific Officer for Abeome, Distinguished Research ...
Cached Biology Technology:Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 2Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 3Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 4Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 5Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 6Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 2Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 3Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 4Abeome Forms First Class Scientific Advisory Board 2
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and   43 Figures spread ...
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... 2, 2013  Fingerprint Cards, swipe sensor ... well-renowned Asian OEM customer for an additional smartphone scheduled to be launched ... Fingerprint Cards (FPC) has earlier announced multiple mobile and tablet DWs ... Korea, with the first phones in Japan and ...
... is a bacterium that establishes a life-long stomach infection in ... or stomach cancer. New research, presented at this week,s Society ... of how these bacteria can manipulate the human immune system ... Researchers from the University of Nottingham have shown that ...
... the world have watched as strain after strain of the ... Over the last few decades researchers have used ... individual mutations that allow TB to withstand many of the ... markers serve as clues for new drug development and as ...
Cached Biology News:FPC Awarded new Smartphone DW From Existing Prominent Asian OEM Customer for Launch With Leading US Operator 2Stomach bacteria switch off human immune defences to cause disease 2Researchers untangle genetics of drug resistant TB 2Researchers untangle genetics of drug resistant TB 3Researchers untangle genetics of drug resistant TB 4
Human ICAT Affinity Purified Polyclonal Ab...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
Biology Products: